Jeffrey Coleman

One of the key recurring motifs of TNF—and a huge part of the manuscript sat here on my desk—is how today’s dads are doing the work to identify the inherited traumas passed down by generations of fathers before them, and becoming the circuit breakers to prevent them from going any further. Jeffrey Coleman recently got in touch to share a personal reflection on this work. He lives in Paris with his wife and daughters, works as a coach and community organiser, and writes The Bridge.

As part of a push to increase competition and lower drug prices, the U.S. Senate recently passed a bill that limits the number of patents that can be asserted in biosimilar litigation. The Affordable Prescriptions for Patients Act of 2023 (S.150) mandates that a maximum of 20 patents — with some exceptions — can be asserted against a biosimilar competitor in a Biologics Price Competition and Innovation Act (BPCIA) action.

Since its enactment in 2022, the validity of the Inflation Reduction Act (IRA) and its drug price negotiation program (Program) has been repeatedly challenged in District Court, with little success. Boehringer Ingelheim's lawsuit against the U.S. Department of Health and Human Services (HHS) is the latest challenge to be rejected by a federal court. Boehringer Ingelheim (BI) filed a lawsuit in the District of Connecticut on Aug. 18, 2023.